ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018
Rigorous Clinical Trial Design in Public Health Emergencies Is Essential.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluation of Salivary Biomarkers of Periodontal Disease Based on Smoking Status: A Systematic Review.International journal of environmental research and public health · 2022Pooled it
- Evaluation of a COVID-19 convalescent plasma program at a U.S. academic medical center.PloS one · 2022Trial
- Trial
- Health intervention trials involving transgender, transabled and transracial persons in Africa: A scoping review.Public health challenges · 2024Review
- Towards achieving transnational research partnership equity: lessons from implementing adaptive platform trials in low- and middle-income countries.Wellcome open research · 2023Article
- Characteristics analysis for clinical study design relating to COVID-19 based on the database of ClinicalTrials.gov.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial.American heart journal · 2021Article
- Monitoring clinical trials in infectious diseases.Journal of allergy and infectious diseases · 2021Article
- Remdesivir for coronavirus 2019 (COVID-19): More promising but still unproven.Contemporary clinical trials communications · 2020Article
- Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.American heart journal · 2020Article
- Staying updated on COVID-19: Social media to amplify science in thrombosis and hemostasis.Research and practice in thrombosis and haemostasis · 2020Article
- Addressing challenges for clinical research responses to emerging epidemics and pandemics: a scoping review.BMC medicine · 2020Article
- COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisReview
- Evaluating Promising Investigational Medical Countermeasures: Recommendations in the Absence of Guidelines.Health securityArticle
- Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Randomized clinical trials are the most reliable approaches to evaluating the effects of new treatments and vaccines. During the 2014-2015 West African Ebola epidemic, many argued that such trials were neither ethical nor feasible in an environment of limited health infrastructure and severe disease with a high fatality rate. Consensus among the numerous organizations providing help to the affected areas was never achieved, resulting in fragmented collaboration, delayed study initiation, and ultimately failure to provide definitive evidence on the efficacy of treatments and vaccines. Randomized trials were in fact approved by local ethics boards and initiated, demonstrating that randomized trials, even in such difficult circumstances, are feasible. Improved planning and collaboration among research and humanitarian organizations, and affected communities, in the interepidemic periods are needed to ensure that questions regarding the efficacy of vaccines and treatments can be definitively answered during future public health emergencies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.